Developing Oncolytic Viruses
into Cancer Therapeutics
Oncos Therapeutics develops novel cancer therapies based on its next generation oncolytic viruses.
Our lead product candidate, CGTG-102, is a purposefully modified, GM-CSF encoding adenovirus that selectively replicates in and kills tumor cells.
A Phase I study with CGTG-102 will be completed in 2013 and Phase II studies are scheduled to start in 2014.
October 24 2013 Oncos Therapeutics presenting at BioEurope 2013, Vienna
Our next generation oncolytic viruses put tumors to work for medication:
- Replication in cancer cells. 1 virus replicates to thousands, simultaneously killing the host cancer cell. The thousands of new viruses seek to enter and replicate again in new cancer cells, killing them while leaving normal healthy cells unharmed.
- Anti-tumor immune response. Both the oncolysis and the presence of adenoviruses in tumors are strong danger signals to the immune system, mediating significant natural immunologic response against the tumor as shown in our phase I clinical study.
- Fighting metastases: Anti-tumor immunity created by the virus, specific to each patient's cancer is expected to help fight metastases.